Clinical Trials Logo

Filter by:
NCT ID: NCT00190463 Terminated - Malignant Hemopathy Clinical Trials

Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia

Start date: April 2003
Phase: Phase 4
Study type: Interventional

Empirical antifungal treatment is the gold standard for patients who are neutropenic and have persistent fever under broad-spectrum antibiotics. The rational is that fungal infections are difficult to early diagnose, and are life-threatening. Historical trials have shown a small benefit of survival when this strategy is used. According to the drug usde for this strategy, safety and costs may be concerns. However, since this routine practice has been implemented in hematology, new non-invasive biological diagnostic methods are available to early diagnose fungal infections, such as galactomannan antigenemia for aspergillosis. The goal of our study is to show that limiting the administration of antifungals in this setting to patients with clinical foci of infection, or to patients with a positive galactomannan antigenemia reduces the risk of toxicity of the antifungal drug, and has no impact on the overall mortality of patients treated with chemotherapy for hematologic malignancies.

NCT ID: NCT00190346 Terminated - COPD Clinical Trials

Comparison of Humidification Devices During Non Invasive Ventilation, in Acute Respiratory Failure

Start date: December 2001
Phase: N/A
Study type: Interventional

Comparison of humidification devices during non invasive ventilation, in acute respiratory failure. The hypothesis was, due to dead space, lower humidification, a reduced efficiency of the technique (NIV) when HME are used in comparison with HH.

NCT ID: NCT00190216 Terminated - Depression Clinical Trials

Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)

Start date: December 2001
Phase: Phase 3
Study type: Interventional

The hypothesis of this study was that transcranial magnetic stimulation (TMS) focused on hyperfunctional cerebral areas should be more effective in treating depressive symptoms than stimulations not taking into account the functional specificity of the patient. The goal was to compare the effects of "guided" TMS, using neuroimaging to guide TMS on dysfunctional cortical regions individually detected by neuroimaging, with "standard TMS", as used in most studies, over the left prefrontal cortex, and with sham TMS, in patients with resistant depression.

NCT ID: NCT00190203 Terminated - Clinical trials for Malignant Middle Cerebral Artery Infarction

Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts

DECIMAL
Start date: December 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if patients with malignant middle cerebral artery infarction have a better clinical outcome after early decompressive surgery compared to standard medical management.

NCT ID: NCT00190151 Terminated - Healthy Volunteers Clinical Trials

Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora

Start date: September 2004
Phase: N/A
Study type: Interventional

Bacterial resistance to antibiotics has been a growing therapeutic problem since the late 1980s. Resistant strains of pathogenic bacteria can arise through initial selection of resistant strains in the commensal flora. The emergence of fluoroquinolone resistance in the commensal flora will be assessed in 48 healthy volunteers receiving variable doses of ciprofloxacin during 14 days. Emergence of resistance will be correlated to pharmacokinetic characteristics of ciprofloxacin.

NCT ID: NCT00189579 Terminated - Ovarian Cancer Clinical Trials

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.

NCT ID: NCT00184548 Terminated - Trauma Clinical Trials

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

CONTROL
Start date: October 2005
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity. Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been merged.

NCT ID: NCT00180999 Terminated - Clinical trials for Medico-Economic Aspects (Evaluation of Medical Costs Related to the Three Strategies and Evaluation of Cost/Efficacy)

Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course

Start date: February 2002
Phase: Phase 3
Study type: Interventional

Randomised study to compare the effect of r-Hu-EPO administration with transfusion of Red Blood cell concentrates and also with the administration of polyvitamins in anemic and tired patients presenting a bad prognostic in middle course.

NCT ID: NCT00180960 Terminated - Endocrine Tumors Clinical Trials

Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia

Start date: June 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the treatment of a cancerous disease of the peritoneum with complete cytoreductive surgery with intraperitoneal chemohyperthermia using oxaliplatin plus irinotecan. This is a Phase II study with 100 patients. Origins of the tumors: these include colon, rectum, appendix, peritoneum, and endocrine tumors.

NCT ID: NCT00180895 Terminated - Burkitt Lymphoma Clinical Trials

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL